The other question is given Neuren’s drug was recently approved my main question is given Neuren has been granted ODD for the Rett syndrome does this give them 7 year marketing exclusivity or not? The FDA approval for Daybue didn’t mention exclusivity granted for their drug (they got paediatric rare drug PRV) so I am guessing we can also stand to get marketing approval if we fly past phase 3.
https://data-api.marketindex.com.au/api/v1/announcements/XASX:NEU:2A1436933/pdf/inline/fda-approves-daybue-the-first-treatment-for-rett-syndrome
Ann: Trading Halt, page-70
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $79.35M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12658 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 506 | 1 |
View Market Depth
| Last trade - 09.40am 22/05/2024 (20 minute delay) ? |
| NTI (ASX) Chart |
Day chart unavailable